進行乳がんにおけるリボシクリブとフルベストラント併用療法の全生存期間

Slamonら（Wed,）はこの課題を研究した。

www.synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b1 — DOI: https://doi.org/10.1056/nejmoa1911149

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer· 2019 · 1,016 citations
2. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer· 2018 · 1,284 citations
3. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3· 2018 · 1,099 citations
4. Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint· 2011 · 19 citations
5. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro· 2009 · 1,401 citations